Central EU committee makes case for faster EU drug approval process

The EU Committee ENVI recommends that the EU Commission expands its collaboration with the EMA for the faster approval of medicines, concerning the EU's pharmaceutical strategy.


With a world-spanning health crisis behind it, and with its ambition of strengthening the health preparedness on the horizon, providing a better framework for the drug approval process in the EU is needed. This is the recommendation from one of the European Parliament's central committees, ENVI, for the EU's future pharmaceutical strategy.

In practice, ENVI – which is the EU Committee on the Environment, Public Health and Food Safety – proposes that the Commission considers "how already established tools like accelerated authorization, early dialogue, the Prime scheme and expanded guidance can be used to make medicine available to patients at a faster pace," reads the committee's proposal for the EU pharmaceutical strategy, which will be put to a vote next week.

Read the whole article

Get 14 days free access.
No credit card required.

An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Lundbeck chairman demands change: "We can't live with this"

Years of work developing new treatments at Lundbeck has so far come to nothing. This has led chairman Lars Rasmusssen to demand visible results, even though CEO Deborah Dunsire has essentially had to restart development work since she joined the firm in 2018.

Eli Lilly upgrades earnings per share guidance

On Tuesday, US-based pharmaceutical firm Eli Lilly has updated elements of its 2021 financial guidance pertaining to earnings per share (non-GAAP), now expecting USD 7.95-8.05 compared to the previous USD 7.8-8.

Further reading

Related articles

Trial banner

Latest news

See all jobs